GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmiva AB (OSTO:PHARM) » Definitions » Debt-to-EBITDA

Pharmiva AB (OSTO:PHARM) Debt-to-EBITDA : 0.00 (As of Jun. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Pharmiva AB Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Pharmiva AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was kr0.00 Mil. Pharmiva AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was kr0.00 Mil. Pharmiva AB's annualized EBITDA for the quarter that ended in Jun. 2023 was kr-22.72 Mil. Pharmiva AB's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2023 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Pharmiva AB's Debt-to-EBITDA or its related term are showing as below:

OSTO:PHARM's Debt-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 1.375
* Ranked among companies with meaningful Debt-to-EBITDA only.

Pharmiva AB Debt-to-EBITDA Historical Data

The historical data trend for Pharmiva AB's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmiva AB Debt-to-EBITDA Chart

Pharmiva AB Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Debt-to-EBITDA
- - - -

Pharmiva AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Pharmiva AB's Debt-to-EBITDA

For the Biotechnology subindustry, Pharmiva AB's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmiva AB's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmiva AB's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Pharmiva AB's Debt-to-EBITDA falls into.



Pharmiva AB Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Pharmiva AB's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -22.268
=0.00

Pharmiva AB's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -22.724
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2023) EBITDA data.


Pharmiva AB  (OSTO:PHARM) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Pharmiva AB Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Pharmiva AB's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmiva AB (OSTO:PHARM) Business Description

Traded in Other Exchanges
N/A
Address
Sankt Lars Väg 45B, Lund, SWE, 222 70
Pharmiva AB is a medical technology company. It develops innovative antibiotic-free medical products in order to improve vaginal health.

Pharmiva AB (OSTO:PHARM) Headlines

No Headlines